ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS)

15.42
0.31
(2.05%)
Closed July 15 4:00PM
15.42
0.00
( 0.00% )
Pre Market: 4:05AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
15.42
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
12.95 52 Week Range 25.47
Market Cap
Previous Close
15.42
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
728,420
Shares Outstanding
90,953,011
Dividend Yield
-
PE Ratio
-4.57
Earnings Per Share (EPS)
-3.38
Revenue
117M
Net Profit
-307M

About Arcus Biosciences Inc

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Camden, Delaware, USA
Founded
1970
Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $15.42. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 12.95 to $ 25.47.

Arcus Biosciences currently has 90,953,011 shares outstanding. The market capitalization of Arcus Biosciences is $1.40 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.57.

Arcus Biosciences (RCUS) Options Flow Summary

Overall Flow

Bullish

Net Premium

1M

Calls / Puts

100.00%

Buys / Sells

63.64%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

RCUS Latest News

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (β€œTaiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.7212.554744525513.715.5313.5751043214.64318617CS
4-0.78-4.8148148148116.216.81513.5787498515.41018721CS
120.654.4008124576814.7718.0713.5772842015.85828136CS
26-1.77-10.296684118717.1920.3113.5778470816.58497643CS
52-6.53-29.749430523921.9525.4712.9578158817.3505794CS
156-13.53-46.735751295328.9549.112.9585365023.73725004CS
2607.1185.5595667878.3149.16.370518924.03977884CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CDTConduit Pharmaceuticals Inc
$ 0.4301
(79.21%)
1.97M
WNWMeiwu Technology Company Ltd
$ 1.37
(53.93%)
413.21k
SIEBSiebert Financial Corporation
$ 2.17
(26.16%)
26.83k
INVOINVO BioScience Inc
$ 1.02
(25.79%)
1
PASGPassage Bio Inc
$ 1.08
(17.23%)
10
AMIXAutonomix Medical Inc
$ 1.12
(-18.84%)
64.56k
GRNQGreenpro Capital Corporation
$ 0.98
(-16.95%)
4.95k
CYNCYNGN Inc
$ 7.77
(-15.36%)
793
AREBAmerican Rebel Holdings Inc
$ 0.581
(-13.67%)
10.04k
DATSDatChat Inc
$ 1.66
(-12.17%)
16.75k
CDTConduit Pharmaceuticals Inc
$ 0.4223
(75.96%)
1.99M
WNWMeiwu Technology Company Ltd
$ 1.37
(53.93%)
413.25k
SLNASelina Hospitality PLC
$ 0.0661
(5.59%)
209.04k
SISIShineco Inc
$ 1.03
(5.10%)
184.14k
MAXNMaxeon Solar Technologies Ltd
$ 0.2211
(-2.60%)
176.09k

RCUS Discussion

View Posts
PennyWorld PennyWorld 11 months ago
https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
πŸ‘οΈ0
conix conix 2 years ago
Biotechs are starting to react to news...finally.
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
πŸ‘οΈ0
lovetc lovetc 4 years ago
Also in the DEF 14.....didnt see any information regarding Gilead....
πŸ‘οΈ0
lovetc lovetc 4 years ago
shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
Bought another 1000 shares on that dip, going to wait this one.
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
RCUS getting ready to pop to 33-35 dollars.
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
This is my letter to the shorts with margin account


That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
πŸ‘οΈ0
dinogreeves dinogreeves 4 years ago
News could come from GI*LD that there is a buyout. Watch for news.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock